Flow Cytometry for the Detection and Quantification of Mast Cells in Lymph Nodes: A Prospective Study in 64 Dogs With Mast Cell Tumour.
canine
cytology
mastocytoma
metastasis
nodal
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
revised:
16
09
2024
received:
13
05
2024
accepted:
18
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
Nodal metastasis is a negative prognostic factor in dogs with mast cell tumours (MCTs), thus early detection enables more informed decision-making and provides valuable prognostic information. The aim of this study is to assess the concordance between histopathologic findings of LNs and cytology and flow cytometry (FC), respectively, and to evaluate the ability of FC to differentiate between metastatic (HN2-HN3) and non-metastatic (HN0-HN1) LNs. Overall, 117 LNs from 64 dogs with first occurring MCTs were submitted for cytology, histology and FC. LNs were cytologically and histologically classified according to Krick and Weishaar systems, respectively. Using FC, mast cells (MCs) were identified as IgE+ CD117+ CD5- CD21- cells and quantified as a percentage. When compared with histologic classification, cytology showed an accuracy of 88.2% in distinguishing between metastatic and non-metastatic LNs but did not detect 25.3% of metastatic cases. FC revealed an increase in the median percentages of MCs across histologic classes, progressing from HN0 to HN3. ROC curves pinpointed 0.3% as the optimal cut-off for distinguishing between metastatic and non-metastatic LNs, with an accuracy of 84.3%. A 1.1% cut-off proved valuable in identifying HN3 LNs. The combined interpretation of cytology and FC increased accuracy to 92.2%. An algorithm for guiding the combined interpretation of cytology and FC is suggested based on these findings. In conclusion, FC proves beneficial in enhancing the early detection of metastatic LNs, particularly when utilised alongside cytology. Histopathology remains essential for confirmation, enabling the discrimination of HN classes or, in doubtful cases, for the detection or exclusion of nodal metastases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European College of Veterinary Internal Medicine -Companion Animals (ECVIM-CA) Clinical Studies Fund (CSF)
Organisme : Purina Institute Resident Research Awards (2020)
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
L. Blackwood, S. Murphy, P. Buracco, et al., “European Consensus Document on Mast Cell Tumours in Dogs and Cats,” Veterinary and Comparative Oncology 10, no. 3 (2012): e1–e29.
D. Stefanello, P. Buracco, S. Sabattini, et al., “Comparison of 2‐ and 3‐Category Histologic Grading Systems for Predicting the Presence of Metastasis at the Time of Initial Evaluation in Dogs With Cutaneous Mast Cell Tumors: 386 Cases (2009–2014),” Journal of the American Veterinary Medical Association 246, no. 7 (2015): 765–769.
H. Baginski, G. Davis, and R. P. Bastian, “The Prognostic Value of Lymph Node Metastasis With Grade 2 MCTs in Dogs: 55 Cases (2001–2010),” Journal of the American Animal Hospital Association 50, no. 2 (2014): 89–95.
C. Chalfon, R. Finotello, S. Sabattini, et al., “Patterns of Nodal Metastases, Biological Behaviour and Prognosis of Canine Mast Cell Tumours of the Pinna: A Multi‐Institutional Retrospective Study,” Veterinary and Comparative Oncology 21, no. 2 (2023): 332–338.
L. Marconato, D. Stefanello, F. Solari Basano, et al., “Subcutaneous Mast Cell Tumours: A Prospective Multi‐Institutional Clinicopathological and Prognostic Study of 43 Dogs,” Veterinary Record 193, no. 1 (2023): e2991.
N. L. Cherzan, K. Fryer, B. Burke, and J. Farrelly, “Factors Affecting Prognosis in Canine Subcutaneous Mast Cell Tumors: 45 Cases,” Veterinary Surgery 52, no. 4 (2023): 531–537.
K. M. Weishaar, D. H. Thamm, D. R. Worley, and D. A. Kamstock, “Correlation of Nodal Mast Cells With Clinical Outcome in Dogs With Mast Cell Tumour and a Proposed Classification System for the Evaluation of Node Metastasis,” Journal of Comparative Pathology 151, no. 4 (2014): 329–338.
E. L. Krick, A. P. Billings, F. S. Shofer, S. Watanabe, and K. U. Sorenmo, “Cytological Lymph Node Evaluation in Dogs With Mast Cell Tumours: Association With Grade and Survival,” Veterinary and Comparative Oncology 7, no. 2 (2009): 130–138.
Q. Fournier, P. Cazzini, S. Bavcar, E. Pecceu, C. Ballber, and R. Elders, “Investigation of the Utility of Lymph Node Fine‐Needle Aspiration Cytology for the Staging of Malignant Solid Tumors in Dogs,” Veterinary Clinical Pathology 47, no. 3 (2018): 489–500.
S. Sabattini, E. Faroni, A. Renzi, et al., “Longitudinal Lymph Node Step‐Sectioning for the Identification of Metastatic Disease in Canine Mast Cell Tumor,” Veterinary Pathology 59, no. 5 (2022): 768–772.
D. Guerra, E. Faroni, S. Sabattini, et al., “Histologic Grade Has a Higher‐Weighted Value Than Nodal Status as Predictor of Outcome in Dogs With Cutaneous Mast Cell Tumours and Overtly Metastatic Sentinel Lymph Nodes,” Veterinary and Comparative Oncology 20, no. 3 (2022): 551–558.
M. Sulce, L. Marconato, M. Martano, et al., “Utility of Flow Cytometry in Canine Primary Cutaneous and Matched Nodal Mast Cell Tumor,” Veterinary Journal 242 (2018): 15–23.
C. Ortolani, Flow Cytometry Today, 1st ed. (Cham: Springer International Publishing, 2022).
M. L. Mutz, B. B. Boudreaux, A. Royal, et al., “Cytologic Comparison of the Percentage of Mast Cells in Lymph Node Aspirate Samples From Clinically Normal Dogs Versus Dogs With Allergic Dermatologic Disease and Dogs With Cutaneous Mast Cell Tumors,” Journal of the American Veterinary Medical Association 251, no. 4 (2017): 421–428.
A. K. Patnaik, W. J. Ehler, and E. G. MacEwen, “Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs,” Veterinary Pathology 21, no. 5 (1984): 469–474.
M. Kiupel, J. D. Webster, K. L. Bailey, et al., “Proposal of a 2‐Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior,” Veterinary Pathology 48, no. 1 (2011): 147–155.
R. S. Horta, G. E. Lavalle, L. N. Monteiro, M. C. C. Souza, G. D. Cassali, and R. B. Araújo, “Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features,” Veterinary Pathology 55, no. 2 (2018): 212–223.
N. Selliah, V. Nash, S. Eck, et al., “Flow Cytometry Method Validation Protocols,” Current Protocols 3, no. 8 (2023): e868.
F. Riondato, A. Poggi, B. Miniscalco, F. Sini, L. Marconato, and V. Martini, “Flow Cytometric Features of B‐ and T‐Lymphocytes in Reactive Lymph Nodes Compared to Their Neoplastic Counterparts in Dogs,” Veterinary Sciences 10, no. 6 (2023): 374.